Risankizumab maintains psoriasis clearance in both bio-naïve, bio-experienced patients
Click Here to Manage Email Alerts
Key takeaways:
- After 1 year of continuous risankizumab use, 55.4% and 55.8% of patients achieved IGA 0 and PASI 100, respectively.
- Patient-reported outcomes indicated improvements in fatigue, pain, itch and life impairment.
After 1 year of continuous use, risankizumab helped patients with moderate to severe plaque psoriasis achieve skin clearance regardless of prior biologic usage, according to a real-world study.
“In clinical trials, risankizumab has demonstrated superiority in skin clearance over other biologics including ustekinumab, adalimumab and secukinumab,” Bruce Strober, MD, PhD, clinical professor of dermatology at Yale University, and colleagues wrote.
However, risankizumab data outside of clinical trials are limited, according to the researchers.
To determine the real-world effectiveness of risankizumab for the treatment of moderate to severe plaque psoriasis, Strober and colleagues conducted a retrospective, observational study using the CorEvitas Psoriasis Registry.
They observed the outcomes of 287 patients (mean age, 48.5 years; 41.1% women) with moderate to severe psoriasis that used risankizumab continuously for 1 year. The average length of psoriasis duration was 16.3 years, with 22.3% of patients having psoriatic arthritis, 57.5% having a history of special area involvement and 53.3% having previously used biologics.
The authors found that after a year of continuous risankizumab use, 55.4% of patients achieved an IGA of 0 and 55.8% achieved PASI 100.
Bio-naïve patients experienced higher success compared with bio-experienced patients in both IGA (66.9% vs. 45.4%) and PASI 100 (66.2% vs. 46.7%). Bio-naïve patients also achieved a 94.4% PASI improvement from baseline after 1 year of treatment, whereas bio-experienced patients achieved 82.3%.
Using the Dermatology Life Quality Index questionnaire, patients ranked 10 life categories on a scale of 0 to 3, with higher scores indicating poorer quality of life.
Based on the questionnaire, patients indicated an 81.1% improvement in quality of life with 67.7% of patients stating that psoriasis no longer affected their quality of life.
Patients also reported a 37.2% improvement in fatigue, 73.6% improvement in skin pain and 71.1% improvement in overall itch. Patients also experienced reductions from baseline in work and activity impairment by 56.7% and 73.7%, respectively.
“In conclusion, this analysis provides real-world evidence to support the use of risankizumab for patients with moderate to severe plaque psoriasis, regardless of prior biologic treatment history,” the authors wrote.